On Tuesday the Food and Drug Administration (FDA) announced they will hold the first public hearing on CBD regulation in food and drinks in an effort to better understand how to control this newly-legal compound and keep consumers safe.
The hearing will be held on May 31, 2019 from 8:00 AM to 6:00 PM at the FDA White Oak Campus in Silver Spring, Maryland.
The FDA wants scientific data and information regarding safety, manufacturing, product quality control, marketing, labeling, and sales of products containing cannabis or cannabis-derived compounds, according to a notice posted earlier today in the Federal Register.
The FDA also said in the statement:
“FDA does not intend for this hearing to produce any decisions or new positions on specific regulatory questions, but this hearing is expected to be an important step in our continued evaluation of cannabis and cannabis-derived compounds in FDA-regulated products.”
CBD (cannabidiol) is a non-psychoactive chemical derived from cannabis that has therapeutic effects including help with pain management and anxiety relief. The US Federal Government legalized CBD derived from hemp on December 20, 2018 when it passed the Agriculture Improvement Act of 2018 (the 2018 Farm Bill).
The FDA has a thorough question and answer about the evolving conversation around cannabis-infused products for people and pets.